Context: Before updating the French guidelines on postoperative pain treatment in 2015, the Pain Committee of the French Society of Anaesthesiology and Intensive Care (SFAR) conducted a survey on the medical use of ketamine in France.
Introduction
In the last ten years, the utilisation of ketamine has greatly changed. It has evolved from a pure sedative/anaesthetic drug to an anti-hyperalgesic drug. Laboratory and clinical investigations have reported the clinical impact of hyperalgesia. It can lead to acute and persistent pain especially after surgery. (1, 2) Studies on the pathogenesis of hyperalgesia have clearly shown the benefit of NMDA receptor antagonists, i.e. ketamine at low doses.
Ketamine administration decreases morphine consumption and opioid-induced hyperalgesia especially in patients with chronic pain. (3, 4) However, reports on the reduction of persistent postoperative pain are scarce and require further study. (5) Moreover, there is no consensus in the literature on an effective regimen in terms of doses and timing.(6) Despite these limitations, publications of studies on the benefit of anti-hyperalgesic ketamine have been followed by widespread use and national societies have published guidelines on the use of ketamine as an anti-hyperalgesic medication. (7) Ketamine has been used for decades to treat chronic pain. However, studies supporting this indication are scarce. RCTs reporting a benefit of ketamine in reducing chronic pain are desperately lacking (8) (9) (10) and guidelines are not available. In this field, the heterogeneity of clinical practices is well known.
In this context, the Pain Committee of the French Society of Anaesthesiology and Intensive Care (SFAR) conducted a survey on the use of ketamine in France. We targeted the three main categories of prescribers: anaesthesiologists, physicians treating chronic pain and physicians in intensive care units and emergency rooms. The results of this survey will be a basis to update French guidelines.
Methods
The SFAR Pain Committee prepared an online questionnaire and the link was nationally distributed to all the members of the SFAR, the French Pain Society (SFETD) and the French Society of Emergency Medicine (SFMU) using e-mail. It was also available through the websites of the societies for 3 months in 2014. The questionnaire included questions (Appendix 1) on demographic data, the type of patients for whom ketamine was prescribed, the doses used, the side effects and safety measures associated with the administration of ketamine. Statistics were performed using Statview ® . For continuous variables, the mean (SD) is reported unless noted otherwise and for categorical variables, the number of patients in each category and the corresponding percentage are given. Comparisons were made using the χ2 test for categorical variables.
Results
A total of 1,388 questionnaires were analysed: 740 (55%) from 3,000 SFAR members, 209 (16%) from 1,271 SFETD members and 389 (29%) from 2,648 SFMU members. Among them, 92% declared that they used ketamine: 97% anaesthesiologists, 86% physicians treating chronic pain, 95% intensive care physicians and 97% physicians working in emergency rooms used ketamine. Details are provided Table 1 . The indications, place of administration and type of patients receiving ketamine varied depending on the physician's speciality.
Among the physicians practicing anaesthesia, ketamine was mostly administered to treat acute pain and as an anti-hyperalgesic medication. Almost all physicians (94%) administered ketamine to unconscious patients in the operating room or the PACU. They used an intraoperative bolus dose followed by an intraoperative continuous infusion in 46% of the cases. Doses could vary with a difference up to a 500 factor for continuous infusion with extreme values varying from 0.01 to 5 mg.kg.h -1 ( Table 2) .
Among the physicians treating chronic pain, the use of ketamine differed significantly in terms of indication, type of patient and location during administration. Ketamine was mostly used to treat neuropathic pain (81%) and cancer pain (73%) in conscious patients in the ward and involved older patients. 51% of the physicians declared that they administered ketamine in palliative care situations. The majority of the physicians administered ketamine with a continuous infusion without a bolus dose. As shown in Table 3 , the doses varied from 0.001 to 1.2 mg.kg.h -1 and duration from 2 to 336 hours. The use of oral ketamine was rare but existed with 13% of the physicians declaring the use of this modality of administration. Our survey did not enable us to describe outpatient ketamine use.
Among the physicians practicing in an emergency room, intensive care or pre-hospital emergency care, ketamine was mostly used to treat acute pain (90%). Respectively, 57% and 60% of the physicians in an emergency room and in intensive care administered ketamine as a sedative/anaesthetic medication. Likewise, 60% and 84% of the physicians in an emergency room and in intensive care used ketamine for its anti-hyperalgesic properties.
Of the physicians who declared that they administered a bolus (90%), 34% could repeat this bolus and the use of a continuous infusion after the initial bolus was more frequent in intensive care (51%) than in emergency practice (30%).
The most feared side effects were the same (Table 4) : psychedelic effects and hallucinations came first. In terms of monitoring during ketamine infusion, 15% of the physicians declared that no monitoring was necessary while 59%, 55%, 59%, 77% monitored heart rate, Sp02, blood pressure and level of consciousness, respectively.
Ketamine was used in children by 21% of the physicians. 29% of them used specific doses for children.
Only 34% of the physicians declared working with institutional protocols on ketamine administration. 48% knew about SFAR guidelines on the use of ketamine as an antihyperalgesic medication.
Discussion
To our knowledge, this is the first study reporting medical practices on the medical use of ketamine in Europe since the description of the benefit of its anti-NMDA properties at subanaesthetic doses. The main result of this survey was that ketamine is widely used. The French observational survey of 200 reported that only 9.2% of patients received intraoperative ketamine (11) . Even if our results reflect the declarative frequency of ketamine used by physicians, our results seemed to show a real change in practice. Its most recent indication, anti-hyperalgesia, has been integrated in daily practice. The other indications were mostly acute and chronic pain. This survey also revealed that practices vary greatly with physicians using ketamine, specifically in terms of dosages, the location of patients during administration and duration of administration.
Ketamine used to prevent hyperalgesia
Since the initial publications,(4, 12) ketamine has been promoted for its anti-hyperalgesic properties. Despite some positive results,(13) its definitive benefit in preventing PPP is still in question, mostly owing to the lack of evidence and the need for further studies. Definitive evidence-based clinical proof is desperately lacking. The last meta-analysis on the benefit of ketamine in cancer pain treatment supported a significant but weak effect (23) .
When analysing this review in detail, only 5 studies met the criteria for inclusion: 2 concerned perimedullar ketamine and one oral ketamine, one was negative and the only positive study showed a benefit only up to 12 hours after continuous IV ketamine injection. Evidence is clearly lacking. No consensus could be formulated on doses, which varied from 0.05 to 0.5 mg.kg.h -1 . The evidence of ketamine for the treatment of chronic non-cancer pain, especially syndromes with a neuropathic component, was recently analysed in 2 systematic reviews.(9, 10) Current data on short-term infusions indicated that ketamine produces potent analgesia only during administration. Only 3 studies have reported long-term analgesic affects up to 3 months following prolonged infusion (4 to 14 days). However, a return to pre-treatment pain scores was observed.(24-26) None of these studies showed an improvement in quality of life or function. Dose, duration and modalities of administration are still unknown.
Ketamine is therefore currently not recommended as routine treatment for chronic pain. In our survey, the respondents had the opportunity for comments. Several of them asked for recommendations on the subject. Formal guidelines would be impossible to formulate owing to the lack of evidence-based data but precautions and limits could be published by scientific societies.
Ketamine side effects
The side effects of Ketamine reported by clinicians have varied from hallucination, nausea/vomiting, sedation, vertigo, tachycardia and hypertension, increased cardiac output to intracranial hypertension. (9, 27) A large intra-and inter-individual variability has been observed in the literature and clinicians are unable to predict their occurrence and their severity. This is the reason it would appear to be important to control the use of ketamine outside a secure environment, particularly during administration in a ward or outside a hospital. None of the long-term side effects was reported in our survey even by clinicians who use ketamine to treat patients with chronic pain. The risks of hepatotoxicity, bladder complications and memory defects are probably unknown by most clinicians. Likewise, liver function monitoring has not been reported and more than one out of ten clinicians declared not monitoring anything during ketamine infusion. This practice, which is more likely to be applied by ketamine believers, highlights the urgent need to improve our practice. In addition, such medical ketamine use is evolving toward recreational use in France. (28) A survey has intrinsic bias that cannot be denied. The possibility of a response bias exists, since those who responded may have been more likely to use ketamine. However, the relatively high number of answers for this type of survey in France could be considered as a good picture of current practice. Another bias is that surveys are inevitably declarative and they might not represent current clinical practice. Finally, some answers to the questions were missing or not appropriate and therefore not presented. This might be due to the ambiguity of some questions or the possibility of free answer.
In conclusion, the results of the survey reinforced the need for updated guidelines on ketamine administration. Hyperalgesia prevention is now part of clinical practice but the modalities of ketamine administration need to be further defined. As for acute and chronic pain treatment, the lack of proven benefit and the warnings already published about toxicity call for urgent recommendations and restrictions on the prescription of ketamine for this indication.
Physician speciality Anaesthesia
Chronic pain Emergency room Intensive care Use of ketamine n = 615 (97%) n = 163 (86%) n = 557 (97%) n = 471 (95%) Patient > 75 years n = 179 (28%) n = 91 (49%) * n = 179 (29%) n = 133 (27%) Patient with chronic pain n = 241 (38%) n = 146 (79%) * n = 128 (21%) n = 169 (34%) Patient without chronic pain n = 286 (45%) n = 64 (34%) n = 258 (42%) n = 210 (42%) Awake patient n = 313 (50%) n = 141 (75%) * n = 305 (50%) n = 247 (50%)
Indications: Hyperalgesia n = 595 (94%) n = 66 (35%) n = 366 (60%) n = 417 (84%) Acute pain n = 609 (96%) n = 79 (42%) n = 551 (90%) n = 455 (92%) Chronic pain n = 212 (34%) n = 145 (78%) n = 121 (20%) n = 167 (34%) Narcotic n = 388 (61%) n = 34 (18%) n = 352 (57%) n = 296 (60%) OR / PACU / Intensive Care Unit / ward n = 57 (30%) / n = 54 (29%) / n = 25 (13%) / n = 138 (74%) Table 3 : Administration of ketamine for chronic pain. Data are expressed as mean SD. OR = operating room, PACU = post anaesthesia care unit.
Chronic pain Emergency room Intensive care Monitoring: None n = 134 (21%) n = 24 (12%) n = 63 (10%) n = 80 (16%) Heart rate n = 303 (48%) n = 116 (62%) n = 423 (69%) n = 263 (53%) SpO2 n = 298 (47%) n = 54 (29%) n = 449 (73%) n = 263 (53%) Arterial blood pressure n = 307 (49%) n = 123 (66%) n = 421 (69%) n = 256 (52%) Consciousness n = 456 (72%) n = 131 (70%) n = 506 (82%) n = 384 (78%)
Side effects:
Psychedelic effects n = 501 (79%) n = 127 (68%) n = 473 (77%) n = 397 (80%) Hallucinations n = 434 (67%) n = 108 (58%) n = 433 (70%) n = 339 (68%) Arterial hypertension n = 105 (17%) n = 71 (38%) n = 159 (26%) n = 90 (18%) Tachycardia n = 107 (17%) n = 54 (29%) n = 161 (26%) n = 102 (21%) Intracranial hypertension n = 98 (16%) n = 26 (14%) n = 161 (26%) n = 85 (17%) Sedation n = 130 (21%) n = 66 (34%) n = 221 (36%) n = 127 (26%) Vigilance decrement n = 193 (31%) n = 92 (49%) n = 278 (45%) n = 177 (36%) 
